Author: Ken Dropiewski

Orchestra BioMed™ Appoints Drug-Device Combination Expert Jagdish Parasrampuria as Vice President of Pharmaceutical Development

NEW HOPE, Pa., July 13, 2020 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company focused on developing transformative therapeutic products for large unmet needs in procedure-based medicine, today announced the appointment of Jagdish Parasrampuria M.Pharm., Ph.D., as Vice President of Pharmaceutical Development. Dr. Parasrampuria […]

Cytokinetics Announces Licensing Collaboration and Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor

$250 Million in Committed Capital to Cytokinetics; Additional $200 Million in Development and Commercialization Milestone Payments Ji Xing Pharmaceuticals to Develop & Commercialize in China RTW Provides Access to Capital to Cytokinetics to Fund Global Development in Exchange for Potential Royalties and Agrees to Purchase Royalty on Mavacamten Company to Host […]

Benefits of Stereotaxis Robotic Technology in COVID-19 Patient Highlighted in Publication

ST. LOUIS, July 13, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in the European Heart Journal highlighting the benefits of Stereotaxis’ robotic technology in a COVID-19 patient. The publication concludes that catheter ablation “should be […]

Quantum Genomics Enrolls First Patient in Its Pivotal Phase III FRESH Trial of Firibastat in Difficult-to-treat and Resistant Hypertension

PARIS and NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, today announced the enrollment of the first patient in the Company’s […]

Venus Medtech to Partner with Pi-Cardia to Bring its Leaflex(TM) Aortic Valve Technology to China

HANGZHOU, China and REHOVOT, Israel, July 14, 2020 /PRNewswire/ — Venus Medtech (Hangzhou) Inc. (stock code: 2500.HK), the leading transcatheter heart valve medical device player in China, and Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating heart valve calcification, announced today a collaboration to bring Pi-Cardia’s Leaflex™ technology to China. Pi-Cardia’s […]

Abbott Agrees to Global Transcatheter Litigation Settlement with Edwards Lifesciences

ABBOTT PARK, Ill., July 13, 2020 /PRNewswire/ — Abbott (NYSE: ABT) announced today it has reached an agreement with Edwards Lifesciences Corporation to settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products. The agreement will result in the dismissal of all pending cases or appeals […]

FDA Grants the Doraya AHF Catheter Breakthrough Designation

NETANYA, Israel, July 14, 2020 /PRNewswire/ — Revamp Medical, a medical device company developing a percutaneous device for the treatment of acute heart failure (AHF), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the Doraya™ device. The Doraya is a temporary catheter, placed in the […]

HD Medical Awarded FDA Clearance For HD Steth

Intelligent Stethoscope with Integrated ECG delivers Instant Cardiac Insights SANTA CLARA, Calif.–(BUSINESS WIRE)–HD Medical, Inc. of Silicon Valley today announces that its flagship product, HD Steth, has received FDA clearance for all three product classification codes of DQD, DQC and DPS for Electronic Stethoscope, Phonocardiograph and Electrocardiograph combined into one device. HD Steth utilizes […]

SINOMED® Completes One-Year Follow-Up of the PIONEER-III European, US and Japanese Trial of the BuMA Supreme® Coronary Drug-Eluting Stent

TIANJIN, China, July 13, 2020 /PRNewswire/ — SINOMED, a developer of innovative neuro- and cardiovascular technologies, announced the completion of the 1-year follow-up in the PIONEER-III, randomized global trial evaluating the BuMA Supreme Drug-Eluting Coronary Stent (DES). Once completed, the company plans to submit the data to the U.S. Food and Drug […]